The activation of poly (ADP-ribose) synthetase (PARS) subsequent to DNA damage caused by reactive oxygen or nitrogen species has been implicated in several pathophysiological conditions, including ischemia-reperfusion injury and shock. The aim of this study was to investigate whether PARS inhibitors could provide protection against renal ischemia-reperfusion injury in the rat in vivo. Male Wistar rats were subjected to 45 min bilateral clamping of the renal pedicles, followed by 6 h reperfusion (control animals). Animals were administered the PARS inhibitors 3-aminobenzamide, 1,5-dihydroxyisoquinoline, or nicotinamide during the reperfusion period. Ischemia, followed by reperfusion, produced significant increases in plasma concentrations of urea, creatinine, and fractional excretion of Na ؉ (FE Na ) and produced a significant reduction in glomerular filtration rate (GFR). However, administration of the PARS inhibitors significantly reduced urea and creatinine concentrations, suggesting improved renal function. The PARS inhibitors also significantly increased GFR and reduced FE Na , suggesting the recovery of both glomerular and tubular function, respectively, with a more pronounced recovery of tubular function. In kidneys from control animals, histological examination revealed severe renal damage and immunohistochemical localization demonstrated PARS activation in the proximal tubule. Both renal damage and PARS activation were attenuated by administration of PARS inhibitors during reperfusion. Therefore, we propose that PARS activation contributes to renal reperfusion injury and that PARS inhibitors may be beneficial in renal disorders associated with oxidative stress-mediated injury.-Chatterjee, P. K., Zacharowski, K., Cuzzocrea, S., Otto, M., Thiemermann, C. Inhibitors of poly (ADP-ribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo. FASEB J. 14, 641-651 (2000)
Renal ischemia is one of the most common causes of acute renal failure (1) . Reperfusion of previously ischemic renal tissue initiates a complex and interrelated sequence of events that results in injury and the eventual death of renal cells due to a combination of apoptosis and necrosis (2) . Although reperfusion is essential for the survival of ischemic tissue, there is good evidence that reperfusion itself causes additional cell injury (reperfusion injury) (3), which has been attributed to adenosine triphosphate (ATP) depletion, intracellular calcium accumulation, phospholipase activation and membrane lipid alterations, cytoskeletal dysfunction, neutrophil infiltration, and the generation of reactive oxygen species (ROS) (3, 4) . ROS-mediated cell injury and death has been implicated in the pathogenesis of renal ischemia-reperfusion injury and associated renal failure (5) . The situation is particularly complex in the kidney, as ischemia itself can cause early irreversible damage, which also appears to be mediated by ROS (3, 5) .
ROS produce cellular injury and necrosis via several mechanisms including peroxidation of membrane lipids, protein denaturation, and DNA damage (4) . Evidence from studies using cultured cells have demonstrated that ROS produce strand breaks in DNA that trigger activation of the nuclear enzyme poly (ADP-ribose) synthetase [PARS, EC 2.4.2.30, also referred to as poly (ADP-ribose) polymerase (PARP) or poly (ADP-ribose) transferase (pADPRT) (6) ]. PARS is an abundant, chromatin-bound enzyme constitutively expressed in most cell types (7) . It is an energy-consuming enzyme thought to be involved in DNA repair (6) , although its true physiological role is still unclear (8) . Once activated, PARS catalyzes the transfer of ADP-ribose moieties from NAD to nuclear proteins, including histones, and onto PARS itself (automodification) with the concomitant formation of nicotinamide (NIC) (9) . However, there is now good evidence that exposure of cells to oxidant stress results in strand breaks in DNA leading to an excessive activation of PARS, resulting in the depletion of its substrate NAD in vitro and a reduction in the rate of glycolysis (10, 11) . Since NAD functions as a cofactor in glycolysis and the tricarboxylic acid cycle, NAD depletion leads to a rapid fall in intracellular ATP levels (12) (13) (14) (15) . Furthermore, nicotinamide formed by PARS activation can be recycled back to NAD via a mechanism that also consumes ATP (13) . Thus, activation of PARS leads to a fall in ATP via two different mechanisms, leading to cellular dysfunction and ultimately cell death. Overall, this process has been termed the 'PARS suicide hypothesis' (15) .
PARS inhibitors include benzamide analogs such as 3-aminobenzamide (3-AB), NIC, and recently discovered and more potent isoquinoline derivatives such as 1,5-dihydroxyisoquinoline (ISO) (16, 17) . Such compounds have previously been used in both in vivo and in vitro studies to investigate their ameliorative role in various pathophysiological conditions ranging from ischemia-reperfusion injury to diabetes mellitus (17, 18) . PARS inhibitors have been shown to attenuate the fall in ATP (and NAD) and improve the survival of several cultured cell types exposed to reactive oxygen or nitrogen species such as H 2 O 2 or peroxynitrite (18 -23) . Three years ago we reported that the PARS inhibitors 3-AB, ISO, NIC reduce ischemia-reperfusion injury in the rabbit heart and skeletal muscle in vivo (24) . To date, there has been little research into the role of PARS within the kidney in vivo under normal or pathophysiological conditions. We have recently discovered that 3-AB, ISO, and NIC protect primary cultures of rat proximal tubular (PT) cells against H 2 O 2 -mediated oxidant stress (25) . The possibility of pharmacological inhibition of PARS activation in the kidney could lead to the development of novel therapies for the treatment of renal ischemia-reperfusion injury and associated acute renal failure, either alone or in combination with other recognized therapies, since 1) reperfusion injury plays a major role in clinical renal failure, 2) PARS activation has been implicated in ischemia-reperfusion injury in several other organs, and 3) the beneficial effects of PARS inhibitors have been recognized in nonrenal models of ischemia-reperfusion injury. Therefore, the aim of this study was to investigate the effect of PARS inhibitors in an in vivo model of renal ischemia-reperfusion injury in the anesthetized rat.
MATERIALS AND METHODS

Materials
Unless otherwise stated, all compounds used in this study were purchased from Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.). All stock solutions were prepared using nonpyrogenic saline (0.9% w/v NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, U.K.).
Animal preparation
This study was carried out using 113 male Wistar rats (Tuck, Rayleigh, Essex, U.K.) weighing 250 -350 g, receiving a standard diet and water ad libitum, and cared for in accordance with the Home Office Guidance in the Operation of the Animals (Scientific Procedures) Act 1986, published by HMSO, London, U.K. Of these animals, four died during the course of the experiment, giving an overall mortality of 3.9%. All results obtained from rats that died during the course of the experiment were excluded from the data analysis and numbers (n) provided in the text refer to the 'survivors' of the entire experimental period only. All animals were anesthetized with sodium thiopentone (Intraval sodium, 120 mg/kg i.p; Rhone Merieux Ltd., Essex, U.K.), and anesthesia was maintained by supplementary infusions of sodium thiopentone. The animals were placed onto a thermostatically controlled heating mat (Harvard Apparatus Ltd., Kent, U.K.) and body temperature was maintained at 38 Ϯ 1°C by means of a rectal probe attached to a homeothermic blanket. A tracheotomy was performed to maintain airway patency and facilitate spontaneous respiration. The right carotid artery was cannulated (PP50, I.D. 0.58 mm, Portex, Kent, U.K.) and connected to a pressure transducer (Senso-Nor 840, Horten, Norway) for the measurement of mean arterial blood pressure (MAP) and derivation of the heart rate (HR) from the pulse waveform, which were displayed on a data acquisition system (MacLab 8e, AD Instruments, Hastings, U.K.) installed on an Apple MacIntosh computer. MAP and HR were monitored for the duration of each experiment. The jugular vein was cannulated (PP25, I.D. 0.40 mm, Portex, Kent, U.K.) for the administration of drugs. A midline laparotomy was performed and the kidneys located, after which the renal pedicles, containing the renal artery, vein, and nerve supplying each kidney were carefully isolated.
Renal ischemia-reperfusion
Rats were allowed to stabilize for 30 min before they were subjected to bilateral renal occlusion for 45 min using artery clips to clamp the renal pedicles. Reperfusion began once the artery clips were removed ('control' animals). Occlusion was verified visually by change in the color of the kidneys to a paler shade and reperfusion by a blush. Other rats were subjected to sham operation ('sham-operated' animals; identical surgical procedures but without bilateral renal clamping) and maintained under anesthesia for the duration of the experiment. At the end of all experiments, animals were killed by an overdose of sodium thiopentone. Kidneys were then excised and bisected for histological assessment and measurement of PARS activity as described below. Another group of anesthetized rat were tracheostomized, and the carotid artery and bladder were cannulated as described above for the collection of plasma and urine samples, respectively, after the 30 min stabilization period. These animals are described as 'normal animals' in this report.
Experimental protocol
On completion of surgical procedures, the animals were grouped randomly as described in Table 1 To elucidate the effects of the PARS inhibitors on hemodynamics and organ function in sham-operated rats, separate groups of animals received the treatments described (outlined in Table 1 ). In all the groups of animals described above, hemodynamic parameters were recorded for the duration of the experiment.
Quantification of renal function and injury
At the end of the reperfusion period, blood (1 ml) samples were collected via the carotid artery into S1/3 tubes containing serum gel. The samples were centrifuged (6000 r.p.m. for 3 min) to separate plasma, which was analyzed for biochemical parameters within 24 h after collection (Vetlab Services, Sussex, U.K.). Plasma concentrations of urea were measured as an indicator of impaired renal function and/or increased catabolism (26) and creatinine as an indicator of reduced glomerular filtration rate (26) . Urine samples were also collected during the reperfusion period and the volume of urine produced was recorded. Urine concentrations of creatinine and Na ϩ were also measured (Vetlab Services) and used in conjunction with plasma creatinine and Na ϩ concentrations to calculate glomerular filtration rate (GFR) and fractional excretion of Na ϩ (FE Na ) respectively, using standard formulas. Plasma and urine samples were also collected from normal, sham-operated, and control animals and those treated with vehicle, PARS inhibitors, negative controls, or DEF.
Renal histopathology
Kidneys were fixed in 10% w/v neutral buffered paraformaldehyde, embedded in paraffin, cut into 4 m sections, dewaxed, and stained with hematoxylin-eosin, Fuchsin, and Luxol-fast blue. Histopathological examination for specific lesions characteristic of renal injury (27) was performed by a pathologist blinded to the animal treatment using light microscopy.
Histochemical measurement of PARS activation
PARS activation was assessed in kidneys fixed in 10% w/v neutral buffered paraformaldehyde and 8 m sections were prepared from paraffin embedded tissues. After deparaffination, endogenous peroxidase was quenched using 0.3% v/v H 2 O 2 in 60% methanol for 30 min. The sections were permeablized with 0.1% w/v Triton X-100 in phosphatebuffered saline (PBS, 0.01 M, pH 7.4) for 20 min. Nonspecific adsorption was minimized by incubating the section in 2% v/v normal goat serum in PBS for 20 min. Endogenous avidin and biotin binding sites were blocked by sequential incubation for 15 min using avidin (DBA, Milan, Italy) and biotin (DBA), respectively. Sections were then incubated overnight (18 h) in a 1:500 dilution of primary anti-poly (ADP-ribose) antibody (DBA) or with control solutions consisting of PBS alone or nonspecific purified rabbit IgG (1:500 dilution, DBA). Specific labeling was detected using a biotin-conjugated goat anti-rabbit IgG (DBA) and avidin-biotin peroxidase (DBA). Samples were then viewed under a light microscope.
Statistical analysis
Data are expressed as mean Ϯ se obtained from hemodynamic or biochemical measurements obtained from n animals. Statistical analysis was carried out using GraphPad Prism/Instat (GraphPad Software, Calif.). Data were analyzed using one-way ANOVA, followed by Dunnett's post hoc test, and a P value of less than 0.05 was considered to be significant.
RESULTS
Plasma and urinary biochemical parameters
Animals that underwent renal ischemia-reperfusion injury exhibited significant time-dependent increases in the plasma concentrations of urea and creatinine compared to normal and sham-operated animals (Fig. 1A, Fig. 2A) . Plasma urea and creatinine concentrations demonstrated a steady increase over 2, 4, and 6 h of reperfusion. After 6 h of reperfusion, plasma levels of urea had increased by 3.5-fold, from 8.2 Ϯ 1.1 mmol/l (sham-operated) to 28.3 Ϯ 0.9 mmol/l (6 h reperfusion controls), n ϭ 12, P Ͻ 0.05. Plasma creatinine concentrations increased by 5.7-fold, from 35.3 Ϯ 2.3 mol/l (sham operated) to 201.1 Ϯ 7.4 mol/l (6 h reperfusion controls), n ϭ 12, P Ͻ 0.05. Plasma levels of urea and creatinine beyond 45 min ischemia and 6 h reperfusion were not determined in this study.
In conjunction with plasma creatinine and Na ϩ concentrations, measurement of urine production (urine flow, ml/min) and urinary concentrations of creatinine and Na ϩ allowed the calculation of GFR and FE Na , respectively. GFR, used as an indicator of glomerular function, remained within physiological levels in normal and sham-operated rats (1.27Ϯ0.13 ml/min, nϭ11 and 1.01Ϯ0.12 ml/min, nϭ6, respectively, Fig. 3A ). However, ischemia followed by reperfusion produced a significant reduction in GFR, which was maintained throughout the 6 h reperfusion period (Fig. 3A) . After 6 h reperfusion, GFR was reduced by 97.0% from 1.01 Ϯ 0.12 ml/min (shamoperated), n ϭ 6, to 0.03 Ϯ 0.01 ml/min (6 h reperfusion controls), n ϭ 12, P Ͻ 0.05. Calculations of FE Na were used as an indicator of PT function. FE Na calculated from normal and sham-operated rats remained within normal parameters (0.31Ϯ0.04%, nϭ11 and 0.44Ϯ0.09%, nϭ6, respectively; Fig. 4A ). However, ischemia for 45 min, followed by 2, 4, or 6 h reperfusion, produced a significant increase in FE Na that was maintained throughout the reperfusion period. After 6 h reperfusion, FE Na increased by 98.6% from 0.44 Ϯ 0.09% (sham-operated), n ϭ 6, to 32.1 Ϯ 3.6% (6 h reperfusion controls), n ϭ 12, P Ͻ 0.05 (Fig. 4A) .
Effect of PARS inhibitors on plasma and urinary biochemical parameters
Administration of 3-AB produced a dose-dependent reduction in plasma concentrations of urea and creatinine compared to values obtained from control animals (i.e., 45 min ischemiaϩ6 h reperfusion only) (Fig. 1B, Fig. 2B ). 3-AB produced a significant reduction in plasma urea and creatinine levels at the two higher concentrations administered (10 mg/kg bolus followed by 5 mg/kg/h infusion and 30 mg/kg bolus followed by 15 mg⅐kg Ϫ1 ⅐h Ϫ1 infusion) (Fig. 1B,  Fig. 2B ). 3-AB also produced a significant improvement in GFR at these concentrations (Fig. 3B) . 3-AB reduced FE Na in a dose-dependent manner in comparison with FE Na values obtained from control animals; a significant reduction was obtained using the two highest concentrations (10 mg/kg bolus followed by 5 mg/kg/h infusion and 30 mg/kg bolus followed by 15 mg/kg/h infusion) (Fig. 4B) .
Administration of the PARS inhibitors 3-AB and ISO produced small, but significant, reductions in plasma urea concentrations compared to control values (Fig. 1C) . 3-AB and ISO reduced plasma urea concentrations by ϳ15 (PϽ0.05) and 41% (PϽ0.05), respectively. However, NIC did not reduce urea concentrations compared to control urea concentrations. All three PARS inhibitors produced a significant reduction in plasma creatinine concentrations compared to control values (Fig. 2C) . Compared with control levels, 3-AB, ISO, and NIC reduced plasma creatinine concentrations by ϳ32 (PϽ0.05), 44 (PϽ0.05), and 32% (PϽ0.05), respectively (Fig.  2C ).
All three PARS inhibitors, given before and during 6 h reperfusion, significantly increased GFR (Fig.  3C ) and decreased FE Na (Fig. 4C) compared to control values. 3-AB, ISO, and NIC produced an 85% (PϽ0.05), 79 (PϽ0.05) and 80% (PϽ0.05) increase in GFR, respectively, compared to control GFR values (Fig. 3C) . The PARS inhibitors also produced significant decreases in FE Na of 61% (PϽ0.05), 57% (PϽ0.05), and 48% (PϽ0.05), respectively, vs. FE Na values obtained from controls (Fig. 4C) .
Administration of 3-ABA and NICA [structural analogs of 3-AB and NICA that do not inhibit PARS activity (16) and were used as negative controls in this study] had no effect on plasma urea or creatinine concentrations when compared with values obtained from control animals (Fig. 1D, Fig. 2D ). However, administration of the iron chelator DEF (positive control) before and during reperfusion produced significant reductions in plasma urea and creatinine concentrations of ϳ36 (PϽ0.05) and 30% (PϽ0.05), respectively (Fig. 1D, Fig. 2D ).
Neither 3-ABA nor NICA had any effect on GFR or FE Na compared with control values (Fig. 3D, Fig.  4D ). However, administration of DEF before and during reperfusion produced a significant increase in GFR (70%; PϽ0.05) and a significant decrease in FE Na (55%; PϽ0.05), respectively, compared to control values (Fig. 3D, Fig. 4D ).
Administration of any of the drugs used in this study to sham-operated animals for the duration of the experiment had no effect on plasma urea and creatinine levels, GFR, or FE Na and were similar to those obtained from normal and sham-operated animals (data not shown).
Renal histopathology and effects of PARS inhibitors
Compared with sham-operated rats (Fig. 5A) , rats that underwent ischemia for 45 min, followed by reperfusion, demonstrated the recognized features of renal injury including characteristic histo- logical signs of glomerular and tubular damage (27) . After 6 h reperfusion, degeneration of the glomeruli, tubular dilatation, tubular swelling and necrosis, luminal congestion, and the presence of eosinophilia were observed (Fig. 5B) . The histological signs of renal injury were also apparent after 2 and 4 h of reperfusion (data not shown), but increased noticeably after 6 h reperfusion (Fig.  5B) .
Kidneys obtained from rats treated with PARS inhibitors 1 min prior to and during reperfusion demonstrated reduced histological features of renal injury when compared with kidneys obtained from control animals (Fig. 5C ). The example illustrated (Fig. 5C) shows an example of rat kidney obtained after administration of 3-AB. Although substantial glomerular degradation is still observed, there appears to be reduced tubular swelling and dilatation, luminal congestion, and eosinophilia compared with that observed in kidneys obtained from control animals.
Immunohistochemical localization of PARS and actions of PARS inhibitors
Kidneys obtained from rats subjected to ischemiareperfusion demonstrated noticeable staining for PARS when compared with kidneys obtained from sham-operated rats (Fig. 6A, B) , suggesting the activation of PARS after 45 min ischemia, followed by 6 h reperfusion. In these control rats, staining for PARS (P) was most marked in the PT cells, with surrounding structures largely unaffected (Fig. 6B) . The same level and distribution of staining for PARS were obtained from kidneys removed after 2 and 4 h of reperfusion (data not shown).
Kidneys obtained from rats subjected to ischemiareperfusion in the presence of the PARS inhibitors demonstrated markedly reduced staining for PARS protein when compared with kidneys obtained from control animals (Fig. 6C , suggesting a reduction in the activation of PARS after 6 h reperfusion. Figure  5C shows a section from a representative rat kidney obtained after administration of 3-AB. 
DISCUSSION
There is good evidence from both in vivo and in vitro studies that 1) ROS are implicated in renal ischemiareperfusion injury (5), 2) ROS produce strand breaks in the DNA of renal tissues (28) , and 3) strand breaks in DNA activate PARS (10) . Therefore, our hypothesis is that the activation of PARS may contribute, in part, to the injury associated with ischemia-reperfusion of the kidney and contributes to the associated acute renal failure and eventual endstage renal failure. We have recently discovered that three recognized PARS inhibitors (3-AB, ISO, and NIC) reduce the cellular injury and death caused by H 2 O 2 in PT cell cultures isolated from rat kidneys (25) . We now demonstrate here, for the first time, that the same PARS inhibitors reduce ischemiareperfusion injury in the rat kidney in vivo.
Ischemia followed by reperfusion of rat kidneys produced significant increases in plasma concentrations of urea, suggesting impaired renal function and/or increased catabolism, as well as increased plasma concentrations of creatinine, indicating reduced GFR and hence renal failure (26) . In this study, a significantly reduced GFR and increased FE Na were recorded from control animals, indicating marked reduction in glomerular and PT function, respectively. These biochemical indicators of renal dysfunction appeared to be dependent on the time period of reperfusion, with maximal changes in urea, creatinine, GFR, and FE Na observed after 6 h reperfusion. These indicators of renal function were not measured beyond 6 h. However, it has recently been demonstrated that there are no significant increases in plasma urea and creatinine levels between 6 and 24 h of reperfusion in a similar model of renal ischemia-reperfusion in the rat (29) . Histological evaluation confirmed renal injury after 6 h of reperfusion, with the characteristic morphological markers of tissue damage present in kidneys obtained from control animals.
The ability of ROS, including hydroxyl radicals, to induce renal injury has been demonstrated (3, 5, 28) . The renal dysfunction produced during reperfusion of previously ischemic rat kidneys in this study appears to be secondary to the generation of hydroxyl radicals, as it was attenuated by desferrioxamine. Desferrioxamine, an iron chelator that binds and subsequently reduces the availability of Fe 2ϩ , which in combination with H 2 O 2 promotes the generation of hydroxyl radical, has previously been shown to protect rabbit kidneys against both cold and warm ischemic injury (30, 31) . ROSmediated mechanisms of renal tissue injury and necrosis such as DNA damage are likely to be a major player in renal ischemia-reperfusion injury, as it is still unclear whether lipid peroxidation is a major contributor to the renal dysfunction associated with ischemia-reperfusion (32, 33) .
The results obtained in this study suggest that the activation of PARS contributes, in part, to the renal dysfunction and injury observed after reperfusion of previously ischemic tissue. This hypothesis is supported by the following key findings: 1) three chemically distinct PARS inhibitors significantly reduced plasma urea and creatinine levels, increased GFR, and reduced FE Na when administered before and during reperfusion; 2) PARS activation in the PT was demonstrated histochemically; 3) 3-ABA and NICA, analogs of 3-AB and NIC, which do not inhibit PARS activity (16) , did not reduce the renal dysfunction/ injury caused by ischemia-reperfusion. Thus, we propose that ischemia-reperfusion causes an increase in PARS activity in the PT, which in turn contributes to the cellular injury and death observed under these conditions. This hypothesis is reinforced by our earlier findings that the PARS inhibitors can protect primary cultures of rat PT cells against oxidant stress-mediated cell injury and death (25) .
Ischemia-reperfusion of the kidney causes glomerular and tubular dysfunction and injury (34) ; in this study, ischemia-reperfusion produced a marked reduction in GFR (an indicator of glomerular dysfunction) and also an increase in FE Na (an indicator of tubular dysfunction), both of which were maintained throughout the reperfusion period. Administration of PARS inhibitors during this period produced a modest but significant increase in GFR, suggesting some degree of recovery of glomerular function. This was reflected in the reduced plasma urea and creatinine concentrations in rats administered PARS inhibitors during reperfusion. However, it could be argued that although plasma urea concentrations were reduced in the presence of 3-AB and ISO, NIC did not have an effect. This is not surprising, since it is known that urea clearance as a measure of renal function is imprecise as it can be influenced both by extrarenal factors and urine flow (26) . Therefore, assessment of creatinine clearance is a much better marker of renal function (26) .
Although the PARS inhibitors produced a small, but significant, recovery in GFR, the effects of the PARS inhibitors on the increase in FE Na caused by ischemiareperfusion were more pronounced. This suggests that the protection afforded by the PARS inhibitors is greater against the PT effects of reperfusion injury than those in the glomerulus. This is confirmed by the immunohistochemical staining for PARS, which is present only in the PT in kidneys obtained from control rats but absent in kidneys from rats administered the PARS inhibitors. Further evidence has been reported in our earlier findings that PARS inhibitors protect cultured rat PT cells against oxidant stressmediated cellular injury and death (25) . Figure 6 . Immunohistochemical localization of PARS; Rats were subjected to A) sham operation; B) 45 min ischemia, followed by 6 h reperfusion (control); and C) 45 min ischemia, followed by 6 h reperfusion in the presence of 3-AB. PARS activation (P) was identified using immunohistochemical localization after involving specific labeling using a biotinconjugated goat anti-rabbit IgG and avidin-biotin peroxidase. Arrows indicate regions where PARS activation can be observed. Original magnification: ϫ200. Figure 5 . Histological examination of rat kidneys; Rats were subjected to A) sham operation; B) 45 min ischemia, followed by 6 h reperfusion (control); and C) 45 min ischemia, followed by 6 h reperfusion in the presence of 3-AB. Kidneys were stained with hematoxylin-eosin, Fuchsin, and Luxol-fast blue before viewing under a light microscope. For control kidney, the following are marked: degeneration of the glomeruli (A), tubular dilatation (B), tubular swelling and necrosis (C), luminal congestion (D), eosinophilia (E). Original magnification: ϫ100.
In this study, 3-AB, which we have previously shown to produce a dose-dependent inhibition of PARS activity in vitro in primary cultures of rat PT cells (25) , produced a significant and dose-dependent improvement in renal function. The concentrations of the three PARS inhibitors used in this study correspond to those used in previous in vivo studies (24, 35) . Furthermore, in the case of 3-AB, the concentration used here in vivo corresponds to a plasma concentration that is 1) within the concentration range that selectively inhibits PARS activity in vitro (36) and 2) corresponds to the concentrations required to inhibit PARS activation by H 2 O 2 in primary cultures of rat PT cells (25) . The continuous infusion regimen selected for the administration of the PARS inhibitors during the reperfusion period was based on the observation that the calculated half-life of 3-AB in the rat in vivo is relatively short at 90 min (37) .
To date, there has been relatively little research into the role of PARS within the kidney or in specific renal structures such as the PT under normal and pathophysiological conditions. Previous reports have described how renal carcinogens produce DNA strand breaks and subsequently increase in poly (ADP-ribosyl)ation of nuclear proteins both in the rat after in vivo administration and in LLC-PK 1 cell cultures, a renal cell line with several PT cell characteristics (38, 39) . Increased PARS activity in murine kidneys has been reported after exposure to cold ischemia in vitro produced by storage at 0°C for up to 72 h (40) . This paper demonstrates for the first time how inhibitors of PARS activation can protect the rat kidney from ischemia-reperfusion injury in vivo. We propose that potent and specific PARS inhibitors may be useful in conditions of oxidative stress that prevail during reperfusion of previously ischemic renal tissues (5) . As ischemic renal injury is becoming one of the main causes of end-stage renal failure (41), the findings described in this study may stimulate interest in the development of more potent and specific PARS inhibitors that could be used either alone or in combination for the treatment of the renal dysfunction associated with reperfusion injury. This is reinforced by the fact that the endogenous PARS inhibitor nicotinamide is currently undergoing clinical trials to investigate its beneficial actions in diabetes mellitus (42) . We therefore propose that the inhibition of PARS activity represents a novel approach for the therapy of renal disorders associated with oxidant stress.
